|
|
| Advancing the Future of Cell & Gene Therapy | This 11-12 November, Cell 2025 unites 1,000+ experts across the CGT value chain to solve key challenges, from scalable bioprocessing and regulatory hurdles to accelerating development. Gain insights across cell culture, therapy development, and CGT manufacturing, and learn from world-renowned leaders Bobby Gaspar (Orchard Therapeutics), Christof Von Kalle, (Research Clinic Luxemburg), and Dame Molly Stevens (University of Oxford). Register Now |
|
|
|
|
In this segment of Cell & Gene Live, our expert panelists, Pratik Jaluria, Ph.D., SVP Technical Development Strategy at BlueRock Therapeutics, Bruno Marques, Ph.D. VP, Process and Product Development at Century Therapeutics, and Kate Rochlin, Ph.D., COO at IN8bio, explain why detecting and quantifying trace levels of cryoprotectants and excipients in cell therapy products involves a risk-based approach, starting with theoretical worst-case calculations based on formulation concentrations and patient exposure limits. |
|
|
| Small Volume ATMP Cryo-Freezing Strategies | White Paper | CPC | Discover best practices for cryopreserving small-volume ATMPs, focusing on sterility, viability, and efficiency with advanced containers and packaging. |
|
|
|
|
|
|
In this episode of Cell & Gene: The Podcast, George Magrath, CEO of Opus Genetics, shares with Host, Erin Harris, how the company is advancing gene therapies for inherited retinal diseases (IRDs), with a focus on LCA5, a rare and severe form of childhood blindness. |
|
|
|
| Mobilizing Community Hospitals To Improve Patient Access To CGTs | Article | By Dr. Sanjay Srivastava, Rahul Mirchandani, and Joe DePinto, InspiroGene | The patient, product, and value chains for cell and gene therapies are far different than traditional healthcare delivery and requires new and specialized sets of capabilities at hospitals. |
|
|
|
| The Resurgence Of Antibody-Drug Conjugates | Article | By Andrew Zupnick, Ph.D., Catalyst Oncology | While scientific and operational hurdles remain, ongoing innovation and improvements in clinical trial design are rapidly expanding the therapeutic reach of ADCs. |
|
|
|
| From Missing To Meaningful: Solving EHR Data Gaps | Article | By Cal Collins, OpenClinica | When data is missing or delayed, it can slow down trial progress. Improving EHR data quality strengthens clinical research and ensures faster access to life-changing therapies for patients in need. |
|
|
| Rapid Results In A High-Stakes Dry Eye Disease Trial | Case Study | TFS HealthScience | This time-sensitive Phase 3 trial in dry eye disease required precision project management leveraging strong site relationships, ophthalmology-specific expertise, and data-driven site selection. |
|
|
CLINICAL TRIALS SOLUTIONS |
|
|
|
|
|
|
|
| Advancing the Future of Cell & Gene Therapy | This 11-12 November, Cell 2025 unites 1,000+ leading experts across the CGT value chain to solve key challenges, from scalable bioprocessing and regulatory hurdles to accelerating development timelines. Gain practical strategies across cell culture, therapy development, and CGT manufacturing, and hear from world-renowned leaders Bobby Gaspar (CEO, Orchard Therapeutics), Christof Von Kalle, (Director & BIH Chair, Research Clinic Luxemburg), and Dame Molly Stevens (University of Oxford). Register Now |
|
|
| Connect With Cell & Gene: |
|
|
|
